CLINICAL_TRIALS
trial_result
· 2020-10-20
Clinical Trial Update: Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis [Phase 3]
Summary
A Phase 3 clinical trial completed evaluating RVL-1201 for Acquired Blepharoptosis with results posted in 2020.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: RVL Pharmaceuticals, Inc. | Conditions: Acquired Blepharoptosis | Phase 3 | Status: COMPLETED | Results posted: 2020-10-20